CACNA1E抗体;CACNA1E Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P11615(CACNA1E Antibody) at dilution 1/15. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P11615(CACNA1E Antibody) at dilution 1/15. (Original magnification: ×200)    

  
  

The CACNA1E gene encodes the α1E subunit of voltage-gated calcium channels (CaV2.3), which form R-type calcium channels critical for regulating cellular excitability, neurotransmitter release, and gene expression. Antibodies targeting CACNA1E are essential tools for studying the expression, localization, and function of these channels in tissues, particularly in the nervous system. These antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate channel distribution in neurons, endocrine cells, and other excitable cells.

CACNA1E has been implicated in neurological disorders, including epilepsy, autism spectrum disorders, and chronic pain, as well as certain cancers due to its dysregulated expression. Research-grade CACNA1E antibodies help elucidate its role in disease mechanisms, synaptic plasticity, and calcium signaling pathways. However, challenges persist due to the channel’s structural complexity, splice variants, and post-translational modifications, which demand antibody specificity validation. Reliable CACNA1E antibodies are crucial for distinguishing CaV2.3 from other calcium channel subtypes and advancing translational studies exploring therapeutic targeting. Recent studies also highlight its potential as a biomarker, driving demand for high-affinity, well-characterized antibodies in both basic research and clinical diagnostics.